AstraZeneca announced today that it has made an equity investment in Cellectis, a clinical-stage biotechnology company.

As a reminder, in the fourth quarter of 2023, Cellectis received an upfront payment of $105 million from AstraZeneca, which included an initial cash payment of $25 million.

An additional equity investment of $140 million, at $5/share, has closed.

After this second investment, AstraZeneca holds a total stake of around 44% in Cellectis.

Copyright (c) 2024 CercleFinance.com. All rights reserved.